Last reviewed · How we verify
Triple oral lipid lowering treatment
Triple oral lipid lowering treatment is a Combination lipid-lowering therapy Small molecule drug developed by Heart Care Foundation. It is currently in Phase 3 development for Hyperlipidemia and dyslipidemia management, Cardiovascular risk reduction in patients with inadequate response to dual therapy.
A combination therapy that simultaneously targets multiple pathways involved in lipid metabolism to reduce cholesterol and triglycerides.
A combination therapy that simultaneously targets multiple pathways involved in lipid metabolism to reduce cholesterol and triglycerides. Used for Hyperlipidemia and dyslipidemia management, Cardiovascular risk reduction in patients with inadequate response to dual therapy.
At a glance
| Generic name | Triple oral lipid lowering treatment |
|---|---|
| Sponsor | Heart Care Foundation |
| Drug class | Combination lipid-lowering therapy |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Triple oral lipid lowering treatment combines three distinct oral agents that work through different mechanisms—typically including a statin (HMG-CoA reductase inhibitor), an ezetimibe (cholesterol absorption inhibitor), and a PCSK9 inhibitor or bempedoic acid—to achieve synergistic reductions in LDL cholesterol, triglycerides, and other atherogenic lipids. This multi-target approach aims to provide superior lipid control compared to dual or monotherapy regimens.
Approved indications
- Hyperlipidemia and dyslipidemia management
- Cardiovascular risk reduction in patients with inadequate response to dual therapy
Common side effects
- Muscle pain or myalgia
- Elevated liver enzymes
- Gastrointestinal upset
- Headache
Key clinical trials
- triPle Oral thERapy With Bempedoic Acid vs uSual Care in Early Lipid Management of Patients With acUte coronAry synDromE (PHASE3)
- Dual vs Triple Lipid-Lowering Therapy in Type 2 Diabetes Mellitus Patients With Elevated LDL Cholesterol (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Triple oral lipid lowering treatment CI brief — competitive landscape report
- Triple oral lipid lowering treatment updates RSS · CI watch RSS
- Heart Care Foundation portfolio CI
Frequently asked questions about Triple oral lipid lowering treatment
What is Triple oral lipid lowering treatment?
How does Triple oral lipid lowering treatment work?
What is Triple oral lipid lowering treatment used for?
Who makes Triple oral lipid lowering treatment?
What drug class is Triple oral lipid lowering treatment in?
What development phase is Triple oral lipid lowering treatment in?
What are the side effects of Triple oral lipid lowering treatment?
Related
- Drug class: All Combination lipid-lowering therapy drugs
- Manufacturer: Heart Care Foundation — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Hyperlipidemia and dyslipidemia management
- Indication: Drugs for Cardiovascular risk reduction in patients with inadequate response to dual therapy
- Compare: Triple oral lipid lowering treatment vs similar drugs
- Pricing: Triple oral lipid lowering treatment cost, discount & access